

## Patient Information Leaflet **SkinVive® by Juvéderm®**

1. NAME AND MODEL.....	1
2. INTENDED PURPOSE / INDICATIONS .....	1
3. CONTRAINDICATIONS, WARNING AND LIMITATIONS FOR USE .....	2
4. SPECIAL OPERATING INSTRUCTIONS FOR USE / PRECAUTIONS.....	2
5. INTENDED PERFORMANCE.....	3
6. UNDESIRABLE SIDE EFFECTS .....	3
7. SYMPTOMS OR SIGNS OF DEVICE OR TREATMENT MALFUNCTION.....	4
8. RISKS & ASSOCIATED PRECAUTIONS .....	5
9. FOLLOW-UP CONSULTATION.....	5
10. DEVICE LIFETIME / DURATION OF TREATMENT EFFECT .....	5
11. COMPOSITION .....	6
12. RESIDUAL MATERIAL .....	6
13. ADDITIONAL INFORMATION / CONTACT.....	6

### 1. NAME AND MODEL

This product is **SkinVive® by Juvéderm®**.

Each box of **SkinVive® by Juvéderm®** contains 2 syringes, each filled with 1 mL hyaluronic acid injectable gel.

#### Product Description / What is **SkinVive® by Juvéderm®**?

**SkinVive® by Juvéderm®** is a smooth, clear, colourless gel which contains:

- hyaluronic acid to help retain natural moisture and softness in the skin,
- lidocaine (local anaesthetic) to help improve comfort to the patient during injection.

### 2. INTENDED PURPOSE / INDICATIONS

#### What is the use of **SkinVive® by Juvéderm®**?

**SkinVive® by Juvéderm®** is an injectable implant intended to treat superficial skin depressions such as fine lines and for additional improvement of skin quality attributes such as hydration and elasticity, via intradermal injection. The presence of lidocaine is meant to reduce the patient's pain during treatment.

**Who can be injected with SkinVive® by Juvéderm®?**

**SkinVive® by Juvéderm®** is indicated for adults (over the age of 18).

**3. CONTRAINDICATIONS, WARNING AND LIMITATIONS FOR USE**

You should **not** use this product if:

- you are pregnant or breastfeeding,
- you suffer from untreated epilepsy,
- you tend to develop scarring,
- you are allergic to hyaluronic acid and/or to gram positive bacterial proteins, as hyaluronic acid is produced by *Streptococcus* type of bacteria,
- you are allergic to lidocaine or to similar local anaesthetics,
- you are suffering from a rare genetic (inherited) disease that causes build-up of porphyrins, which are the building blocks for haemoglobin,
- you are suffering from skin inflammation,
- you are suffering from a skin infection, such as acne or herpes.

Your medical practitioner should not inject **SkinVive® by Juvéderm®** into blood vessels (intravascular injection).

Your medical practitioner should not inject **SkinVive® by Juvéderm®** in the eyelids.

**4. SPECIAL OPERATING INSTRUCTIONS FOR USE / PRECAUTIONS**

**How should SkinVive® by Juvéderm® be used?**

This product is designed to be injected in the appropriate areas requiring treatment by an authorised health care professional who has had appropriate training and experience in injection techniques for filling superficial skin depressions.

**Before treatment:**

Tell your medical practitioner:

1) If you are using the following medications:

- anti-coagulation medication (substances that can prolong bleeding), such as:
  - warfarin,
  - acetylsalicylic acid,
  - nonsteroidal anti-inflammatory drugs,
  - other substances known to increase clotting time such as herbal supplements with garlic or ginkgo biloba.
- medicines that reduce or inhibit hepatic metabolism (cimetidine, beta-blockers). Their use is not recommended due to the presence of lidocaine.

2) If you have had any prior treatments with facial injectables.

3) If you are suffering from any of the following medical conditions:

- History of, or currently suffering from, autoimmune disease or immune deficiency or immunosuppressive therapy. Your medical practitioner will therefore decide on the indication on a case-by-case basis, according to the nature of the disease and its corresponding treatment and shall also advise you if any specific monitoring will be required in your case. Your medical practitioner may also require you to have skin testing for hypersensitivity before any injection is administered and may also refrain from injecting the product if the disease is active.
- History of streptococcal disease (such as recurrent sore throats or acute rheumatic fever). Your medical practitioner may require you to have skin testing for hypersensitivity before any injection is administered. In the event of acute rheumatic fever with heart complications, it is recommended that you do not receive treatment with **SkinVive® by Juvéderm®**.
- Symptoms of heart disease.
- History of severe and/or multiple allergies. According to the nature of the allergy, your medical practitioner will decide on the use of the product as well as whether you require any specific monitoring. In particular, a decision may be taken to propose skin testing for hypersensitivity or suitable preventive treatment for you prior to any injection. If you have a history of anaphylactic shock, it is recommended that you do not receive treatment with **SkinVive® by Juvéderm®**.

You should not have this procedure at the same time as laser treatment, deep chemical peels or dermabrasion. For surface peels, it is not recommended to receive treatment with **SkinVive® by Juvéderm®** if there is significant inflammation from the skin peel treatment still present.

This product is not intended to be injected into an area which has been previously treated with a permanent implant to limit risk of chronic/serious adverse events such as granuloma/areas of inflammation which have been reported with subsequent injections.

There is no clinical data for use of **SkinVive® by Juvéderm®** at an injection volume of greater than 8.0 mL per treatment session. Your medical practitioner will take this into consideration while deciding your treatment plan.

#### **After treatment:**

You should not use any makeup for at least 12 hours following the injection treatment.

You should avoid extended exposure to the sun, ultraviolet (UV) rays and temperatures below 0°C, as well as any sauna or hammam sessions, during the two weeks following the injection treatment.

## **5. INTENDED PERFORMANCE**

**SkinVive® by Juvéderm®** is intended to treat superficial skin depressions such as fine lines and for additional improvement of skin quality attributes such as hydration and elasticity, via intradermal injection. The lidocaine in the gel improves the comfort of the injection by reducing sensitivity to pain.

## **6. UNDESIRABLE SIDE EFFECTS**

### **What are the possible side effects?**

The most common side effects include temporary reactions at the treatment site, which are consistent with other facial-injection procedures.

Potential side effects associated with implantation of this product, which may occur immediately or may be delayed. These include but are not limited to:

- Inflammatory reactions (such as redness or swelling), which may be associated with itching and/or pain on pressure and/or abnormal skin sensation, occurring after the injection. These reactions may last for a week.
- Bruising (haematomas).
- Hardened mass at the injection site.
- Staining or discolouration of the injection site might be observed, especially when the hyaluronic acid dermal filler is injected too superficially and/or in thin skin (Tyndall effect).
- Poor effect or weak filling effect.
- Rare but serious adverse events associated with intravascular injection of dermal fillers in the face and tissue compression have been reported. These complications, which have been reported for facial injections, can include temporary or permanent vision impairment, blindness, slowing down of blood supply to the brain (cerebral ischaemia) or bleeding in that area leading to stroke (cerebral haemorrhage), skin tissue cell-death (necrosis) and damage to underlying tissues/structures.
- Herpes virus reactivations may be provoked in rare cases by direct damage of neuronal axons by the needle or by tissue manipulation and inflammatory reaction after filler injection. The dissection of the subepidermal plane by fanlike needle use may increase the incidence of local adverse events.
- Pus formation, inflammation and immediate or delayed allergic reactions after hyaluronic acid and/or lidocaine injections have also been reported.

Please see section 7: *SYMPTOMS OR SIGNS OF DEVICE OR TREATMENT MALFUNCTION* for further information.

#### **When should I call my medical practitioner?**

If you believe that you have experienced an undesirable effect related to **SkinVive® by Juvéderm®** injectable gel, you should call your medical practitioner and/or the local sponsor of the product, AbbVie Pty Ltd, please see section 13: *ADDITIONAL INFORMATION / CONTACT*.

### **7. SYMPTOMS OR SIGNS OF DEVICE OR TREATMENT MALFUNCTION**

#### **What are the symptoms or signs that could indicate the device is malfunctioning or treatment is not as expected?**

Your medical practitioner will stop the procedure if any of the following symptoms are seen during the injection: changes in vision, signs of stroke, whitening/paling of the skin or unusual pain during or shortly after the procedure.

There are potential side effects associated with implantation of this product, which may occur immediately or may be delayed. Please see section 6: *UNDESIRABLE SIDE EFFECTS* for further information.

#### **What precautions and other measures should you take if the performance of the device changes or if you experience any undesirable side effects?**

##### **Before treatment:**

Your medical practitioner should have discussed with you the product's indications, contra-indications, incompatibilities and potential undesirable effects/risks associated with dermal filler injection and ensure that you are aware of the signs and symptoms of potential complications.

**After treatment:**

Please report the following to your medical practitioner as soon as possible for appropriate treatment:

- inflammatory reactions for more than one week or
- any other side effect that has developed.

If you believe that you have experienced an undesirable effect related to **SkinVive® by Juvéderm®** injectable gel, you should call your medical practitioner and/or the local sponsor of the product, AbbVie Pty Ltd, please see section 13: *ADDITIONAL INFORMATION / CONTACT*.

## 8. RISKS & ASSOCIATED PRECAUTIONS

**What are residual risks?**

Residual risks could arise due to any shortcoming of the protection measures adopted as part of the medical device guideline. Please refer to information provided in section 12: *RESIDUAL MATERIAL*.

**What are risks that could arise from interaction of *SkinVive® by Juvéderm®* with other equipment or material?**

***SkinVive® by Juvéderm®*** does not interact with other medical and/or electrical equipment and is compatible with fields used for magnetic resonance imaging.

Hyaluronic acid is known to be incompatible with quaternary ammonium salts such as benzalkonium chloride.

***SkinVive® by Juvéderm®*** contains lidocaine, there is no known interaction with other local anaesthetics.

Because of the risks associated with treatment with ***SkinVive® by Juvéderm®***, the following precautions and other measures, should be taken:

**By Health care professionals/Medical practitioners:**

***SkinVive® by Juvéderm®*** should never be placed in contact with quaternary ammonium salts such as benzalkonium chloride or with medical-surgical instrumentation which has been treated with this type of substance.

**By the patient:**

Please refer to Section 4: *SPECIAL OPERATING INSTRUCTIONS FOR USE / PRECAUTIONS* for further information with regards to precautions to be followed before and after treatment with ***SkinVive® by Juvéderm®***.

## 9. FOLLOW-UP CONSULTATION

**What is the nature and frequency of regular follow-up, examination, monitoring or maintenance following treatment that you need to undertake?**

It is suggested to have a follow-up consultation with your healthcare professional approximately 2 weeks after the procedure. This is an opportunity to discuss any potential adverse effects you have observed.

A touch-up treatment (for achieving optimal correction) with ***SkinVive® by Juvéderm®*** might be required which can also be completed at this follow-up appointment.

## 10. DEVICE LIFETIME / DURATION OF TREATMENT EFFECT

**What is the lifetime of the product? What could shorten or lengthen the treatment lifetime?**

The correction is temporary. The degree and duration of the correction depend on the character of the defect treated, the tissue stress at the implant site, the depth of the implant in the tissue and the injection technique. It will also vary with the individual patient being treated.

**What precautions and other measures should you take at, or near, the end of the expected treatment lifetime?**

For maintaining optimal correction, a repeat treatment with **SkinVive® by Juvéderm®** might be required. You can contact your medical practitioner for further information.

**Under what circumstances should you contact a health professional in relation to the operation/use of SkinVive® by Juvéderm®?**

Please refer to information provided in section 7: *SYMPTOMS OR SIGNS OF DEVICE OR TREATMENT MALFUNCTION*.

## 11. COMPOSITION

**What material & substances are included in SkinVive® by Juvéderm®?**

Each 1 mL syringe of **SkinVive® by Juvéderm®** contains:

- Hyaluronic acid gel: 12.0 mg,
- Lidocaine hydrochloride monohydrate: 3 mg,
- Phosphate buffer pH 7.2 to make 1 mL.

## 12. RESIDUAL MATERIAL

**What are the manufacturing residuals that could pose a risk to you?**

This product does not contain any manufacturing residuals that can pose a risk to patients.

## 13. ADDITIONAL INFORMATION / CONTACT

**What to do in case of any serious incident that occurs in relation to SkinVive® by Juvéderm®?**

Any serious incident with **SkinVive® by Juvéderm®** should be reported to the manufacturer and to the Therapeutic Goods Administration. If you believe you have experienced an incident/ side effect after treatment with **SkinVive® by Juvéderm®** injectable gel, you should contact Allergan Aesthetics by email to [MedDeviceComplaintsAPAC@AbbVie.com](mailto:MedDeviceComplaintsAPAC@AbbVie.com) or call 1800 252 224 and contact the Therapeutic Goods Administration at <https://www.tga.gov.au/>.

**ALLERGAN**

**Allergan  
Aesthetics**

JUVÉDERM®, SKINVIVE® and their designs are trademarks of Allergan Holdings France SAS, an AbbVie company, or its affiliates.  
DN6959 SkinVive® by Juvéderm® PIL, V 2.0  
Date of preparation: 22 12 2023  
© 2024 AbbVie. All rights reserved.